Table 1.

Baseline characteristics of the patients

Characteristic	Fosaprepitant (n = 174)		Placebo (n = 173)
	Number	Percentage	Number	Percentage
Sex
Male	129	74.1	128	74.0
Female	45	25.9	45	26.0
Age, years
Median	62.0		63.0
Range	26–86		25–85
≥65	70	40.2	84	48.6
History of motion sickness	27	15.5	17	9.8
History of vomiting during pregnancya	17	41.5	18	45.0
Previous treatment with cisplatinb	36	20.7	35	20.2
Alcohol intake
None	87	50.0	111	64.2
<5/week	31	17.8	17	9.8
≥5/week	56	32.2	45	26.0
Type of malignancyc
Respiratory	123	70.7	122	70.5
Genitourinary	17	9.8	16	9.2
Digestive	15	8.6	16	9.2
Head and neck	13	7.5	11	6.4
Other	6	3.4	9	5.2
Cisplatin dosed (mg/m2)
Mean	76.2		76.2
SD	5.6		4.7
Median	76.0		75.4
Range	58.0–126.0		67.9–103.4

^aOnly female subjects who had conceived a child were included.

^bPatients without a history of vomiting (including dry vomiting) were excluded from the patients who had previous treatment with cisplatin.

^cNumber of all subjects in each category.

^dThere were four patients with missing data in the placebo group.